Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203938 · ClinicalTrials.gov registry record · NA
Autism Research Project With Non-Invasive Near-Infrared Light Stimulation
A NA study of Autism Spectrum Disorder, sponsored by University of Texas at Austin.
- Recruiting
- Registry status
- NA
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT06203938: Recruiting NA study of Autism Spectrum Disorder, sponsored by University of Texas at Austin.
NCT06203938 is a NA study of Autism Spectrum Disorder that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 280 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (109% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06203938, a NA study of Autism Spectrum Disorder, is actively recruiting participants, sponsored by University of Texas at Austin.
- RECRUITING
- Registry status
- NA
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators have previously shown that the administration of low-level infrared light is a safe and non-invasive procedure which improves cognition and emotion, as well as enhances brain metabolic activity. Based on previous studies, the investigators hypothesize that this methodology, called low-level light therapy or photobiomodulation, could be used to improve behavioral symptoms in individuals with autism spectrum disorder (ASD).
Primary Outcome
Assess individual differences and changes in autistic traits
Conditions Studied
Interventions
- DEVICE Sham
- DEVICE Transcranial infrared light stimulation
Study Locations (1)
Texas
- Seay Psychology Building, Room 3.304 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06203938 shows while recruiting
NCT06203938 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (109% higher).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT06203938 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06203938 about?
NCT06203938 is a clinical study titled "Autism Research Project With Non-Invasive Near-Infrared Light Stimulation". The investigators have previously shown that the administration of low-level infrared light is a safe and non-invasive procedure which improves cognition and emotion, as well as enhances brain metabolic activity. Based on previous studies, the investigators hypothesize that this methodology, called ...
What is the current status of trial NCT06203938?
This trial is currently recruiting. It is a NA study. The enrollment target is 280 participants. The study started on 2025-01-13. Estimated completion is 2027-12.
What conditions does trial NCT06203938 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT06203938?
The interventions under investigation include: Sham (DEVICE), Transcranial infrared light stimulation (DEVICE).
Who is sponsoring clinical trial NCT06203938?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203938 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06203938's enrollment target sits among peer trials
280 31st of 224 higher than 194 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI